Education
About Us
Working with TipRanks
Follow Us
Novartis AG (GB:0QLR)
LSE:0QLR
0QLR Stock Chart & Stats
CHF119.64
CHF0.25(0.27%)
At close: 4:00 PM EST
CHF119.64
CHF0.25(0.27%)
Day’s Range― - ―
52-Week RangeCHF81.22 - CHF131.02
Previous CloseN/A
Volume210.36K
Average Volume (3M)1.02M
Market Cap
CHF227.43B
Enterprise ValueCHF313.35B
Total Cash (Recent Filing)CHF11.58B
Total Debt (Recent Filing)CHF37.01B
Price to Earnings (P/E)18.3
Beta0.96
Next Earnings
Apr 28, 2026EPS Estimate
1.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.61
Shares Outstanding2,112,421,900
10 Day Avg. Volume801,914
30 Day Avg. Volume1,022,628
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)5.81
Price to Sales (P/S)4.69
P/FCF Ratio14.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF117.85Price Target Upside-1.50% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)8.83
Revenue Forecast (FY)CHF57.37B
Bulls Say, Bears Say
Bulls Say
Acquisition Pipeline ContributionsThe Avidity acquisition adds neuromuscular and other assets viewed as potential multi‑billion dollar opportunities, diversifying growth beyond legacy franchises.
Late‑stage PipelineMultiple mid‑to‑late‑stage programs, including remibrutinib for relapsing multiple sclerosis and expanding Kisqali combination data, create a clear catalyst path that could materially shift the product mix and reduce reliance on older brands.
New Product LaunchesEarly commercial uptake of recent launches such as Pluvicto, Scemblix and Leqvio indicates growing revenue streams that can help offset declines from expiring drugs.
Bears Say
Clinical Program DelaysDelays to several late‑stage development programs reduce the number of near‑term readouts and extend uncertainty around potential approvals and commercialization timelines.
Guidance And Margin PressureCompany guidance implies weaker profit expectations driven by margin dilution and higher net financial expense related to the Avidity transaction, which could constrain operating earnings.
Patent ExpirationsStaggered but substantial patent expirations remain a major overhang and could pressure future sales if new product adoption falls short of expectations.
Novartis AG News
0QLR FAQ
What was Novartis AG’s price range in the past 12 months?
Novartis AG lowest share price was CHF81.22 and its highest was CHF131.02 in the past 12 months.
What is Novartis AG’s market cap?
Novartis AG’s market cap is CHF227.43B.
When is Novartis AG’s upcoming earnings report date?
Novartis AG’s upcoming earnings report date is Apr 28, 2026 which is in 40 days.
How were Novartis AG’s earnings last quarter?
Novartis AG released its earnings results on Feb 04, 2026. The company reported CHF1.608 earnings per share for the quarter, beating the consensus estimate of CHF1.575 by CHF0.032.
Is Novartis AG overvalued?
According to Wall Street analysts Novartis AG’s price is currently Overvalued.
Does Novartis AG pay dividends?
Novartis AG does not currently pay dividends.
What is Novartis AG’s EPS estimate?
Novartis AG’s EPS estimate is 1.67.
How many shares outstanding does Novartis AG have?
Novartis AG has 2,112,421,900 shares outstanding.
What happened to Novartis AG’s price movement after its last earnings report?
Novartis AG reported an EPS of CHF1.608 in its last earnings report, beating expectations of CHF1.575. Following the earnings report the stock price went up 0.926%.
Which hedge fund is a major shareholder of Novartis AG?
Currently, no hedge funds are holding shares in GB:0QLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
0QLR Stock 12 Month Forecast
Average Price Target
CHF117.85
▼(-1.50% Downside)
Technical Analysis
Options Prices
Currently, No data available
---